Galmed Pharmaceuticals Ltd., a leading clinical-stage biopharmaceutical company, has set its sights on revolutionizing the treatment of liver diseases through groundbreaking therapeutic developments. The company currently specializes in the development of Aramchol, an oral therapy that is currently undergoing Phase III studies aimed at treating non-alcoholic steato-hepatitis (NASH) in patients who are either pre-diabetic or have type-II-diabetes mellitus, and are overweight or obese. The company is also assessing the efficacy of Aramchol through a Phase IIa clinical trial known as ARRIVE Study, which focuses on treating HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition to its NASH treatments, Galmed Pharmaceuticals is also exploring the potential of Amilo-5MER, a 5 amino acid synthetic peptide composed of methionine, threonine, alanine, aspartic acid, and valine. The company has entered into several collaborations to further its research, including a partnership with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH. Galmed also has a research and development agreement with MyBiotics Pharma Ltd. to identify the specific microbiome repertoire associated with the response to Aramchol, as well as a license agreement with Samil Pharma Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals was founded in 2000 and has since established itself as a leader in the biopharmaceutical industry. The company's headquarters are located in Tel Aviv, Israel, where it continues to drive innovation and provide hope for countless individuals suffering from liver diseases.
Galmed Pharmaceuticals Ltd.'s ticker is GLMD
The company's shares trade on the NASDAQ stock exchange
They are based in Tel Aviv, Israel
There are 11-50 employees working at Galmed Pharmaceuticals Ltd.
It is https://galmedpharma.com/
Galmed Pharmaceuticals Ltd. is in the Healthcare sector
Galmed Pharmaceuticals Ltd. is in the Biotechnology industry
The following five companies are Galmed Pharmaceuticals Ltd.'s industry peers: